Table of contents
In this issue
p681 | doi:10.1038/nrd1194
Editorial: The balancing act
p683 | doi:10.1038/nrd1196
Research Highlights
Adme: Atomic views of a human P450
p685 | doi:10.1038/nrd1191
Protein degradation: Waste disposal under the spotlight
p686 | doi:10.1038/nrd1183
Pharmacogenomics: Seeing the forest for the trees
p686 | doi:10.1038/nrd1190
Virtual screening: Treasure-hunting tips
p687 | doi:10.1038/nrd1185
Diabetes: Ramping up kinase restores the balance
p688 | doi:10.1038/nrd1186
Drug delivery: Blood vessel
p688 | doi:10.1038/nrd1189
Rheumatoid arthritis: SLAYGLR revealed!
p689 | doi:10.1038/nrd1184
In brief
Transport Proteins | Anticancer Drugs | Neurodegenerative Disease | High-Throughput Screeing
p689 | doi:10.1038/nrd1192
Neurodegenerative diseases: A puff a day keeps the plaques away?
p690 | doi:10.1038/nrd1187
Patent watch
Failing to comply... | Paying twice?
p690 | doi:10.1038/nrd1188
News and Analysis
From the analyst's couch
The optimum time for drug licensing
p691 | doi:10.1038/nrd1181
Fresh from the Pipeline
Adalimumab
p693 | doi:10.1038/nrd1182
Reviews
Article series: A guide to drug discovery
A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States
Janice M. Reichert
p695 | doi:10.1038/nrd1178
Therapeutic antagonists and conformational regulation of integrin function
Motomu Shimaoka & Timothy A. Springer
p703 | doi:10.1038/nrd1174
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Sanjay Kumar, Jeffrey Boehm & John C. Lee
p717 | doi:10.1038/nrd1177
Recent advances in the discovery and delivery of vaccine adjuvants
Derek T. O'Hagan & Nicholas M. Valiante
p727 | doi:10.1038/nrd1176
Anti-TNF-
therapies: the next generation
Michael A. Palladino, Frances Rena Bahjat, Emmanuel A. Theodorakis & Lyle L. Moldawer
p736 | doi:10.1038/nrd1175
Perspectives
Timeline
The trials and tribulations of producing the first genetically engineered drug
Irving S. Johnson
p747 | doi:10.1038/nrd1179
Outlook
A path to improved pharmaceutical productivity
Carl M. Cohen
p751 | doi:10.1038/nrd1180
